Medtronic Vascular, Inc.

Medtronic Ardian Luxembourg S.a.r.l.

Medtronic, Inc.

Medtronic Ireland Manufacturing Unlimited Company

Medtronic Adrian Luxembourg S.a.r.l.

Christopher W Storment

Ayala Hezi-Yamit

Rudy Beasley

Michele Lee Silver

Stefan Stoyanov Tunev

Carol M Sullivan

Jill Mendelson

James Mitchell

Syamala Rani Pulugurtha

Jeffrey W Allen

Susan Edwards

Gerry Oliver McCaffrey

Mingfei Chen

Dustin Thompson

Grainne Teresa Carroll

Aran Murray

Matthew Genovese

Risa Tom Egerter

Jonathan Ashley Cope

Zhongping C Yang

Kevin M Mauch

Rick D McVenes

Gonzalo Martinez

Andrea Jean Asleson

Matthew J Birdsall

Justin Peterson

Mark J Dolan

Mike Krivoruchko

Robert Melder

Ya Guo

Ryan Bienvenu

Stuart Earl Kari

Lance Ensign

Maria Arreguin

D H Perkins

Joseph Traina

Lori Garcia

Joseph A Traina

Peter Glynn

Jack Wallis

Carol Sullivan

Salvador Avelar

Michael Harms

David Shumaker

Dh Perkins

Todd Grodrian

Paul Adler

Stephen Zimmerman

Susan Thornton Edwards

Evaldas Karciauskas

David A Shumaker

Mark M Wegner

Jill P Mendelson

Paus Adler

Gerry Oliver Mccaffrey

Rick D Mcvenes

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. A method can include transluminally delivering a distal portion of an elongated shaft of a catheter to a target renal blood vessel and at least partially inhibiting sympathetic neural activity of a renal nerve. The method includes determining a post-neuromodulation level of one or more biomarkers after at least partially inhibiting the sympathetic neural activity of the renal nerve, wherein the level of the one or more biomarkers directly or indirectly correlates with sympathetic nervous activity in the patient. The method can include comparing the post-neuromodulation level to a predetermined level for the one or more biomarkers, wherein the renal neuromodulation procedure is classified as at least partially successful if the post-neuromodulation level differs from the predetermined level.

Monitoring of neuromodulation using biomarkers

Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.

Protected magnesium alloys for bioresorbable stents

A system for fracturing a frame of a deployed prosthesis with ultrasonic vibration includes a shaft, a tip assembly, an ultrasonic electric generator, and an ultrasonic transducer. The shaft includes a proximal portion and a distal portion. The tip assembly is coupled to the distal portion of the shaft. The tip assembly includes a cutting edge. The ultrasonic transducer is electrically coupled to the ultrasonic generator. Ultrasonic vibration generated by the ultrasonic transducer is translated to the tip assembly. The cutting edge of the tip assembly is configured to focus the vibration of the tip assembly onto a frame of a deployed prosthesis to fracture the frame of the prosthesis. The ultrasonic transducer may be coupled to the proximal portion or the distal portion of the shaft.

Tip assemblies, systems, and methods for fracturing a frame of a deployed prosthesis

A method of forming an electrospun prosthetic valve includes utilizing a rotatable and angularly adjustable prosthetic valve mold. The prosthetic valve mold is set to a first angle. The prosthetic valve mold is rotated at a first rotational velocity and a first layer of electrospun fibers is deposited on the prosthetic valve mold. The prosthetic valve mold is stopped and a frame is positioned over the first layer. The prosthetic valve mold is set to a second angle. The prosthetic valve mold is rotated at a second velocity and a second layer of electrospun fibers is deposited on an outer surface of the first layer and an outer surface of the frame.

Electrospun medical devices and methods of making electrospun medical devices

Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to biomarker sampling in the context of neuromodulation devices, systems, and methods. Some embodiments, for example, are directed to catheters, catheter systems, and methods for sampling biomarkers that change in response to neuromodulation. A system can include, for example, an elongated shaft and a neuromodulation and sampling assembly having a neuromodulation and a sampling element.

Biomarker sampling in the context of neuromodulation devices, systems, and methods

A catheter assembly includes a catheter comprising a flexible elongated member including a distal portion that includes a tubular body defining an inner lumen and a plurality of body apertures that extend through a sidewall of the tubular body into the inner lumen, and a plurality of primary electrodes positioned along the tubular body. The catheter assembly includes a wire defining at least one secondary electrode, the wire being configured to be slidably moved through the inner lumen of the tubular body, where the wire and the plurality of primary electrodes are configured to electrically couple to an energy source that delivers an electrical pulse to a fluid in contact with the plurality of primary electrodes and the at least one secondary electrode to cause the fluid to undergo cavitation to generate a pressure pulse wave within the fluid.

Cavitation catheter

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. One aspect includes a comparison of baseline and post-modulation levels of one or more biomarkers in bodily fluid that have each been collected from a human subject at a relevant time, and that may be used to assess the neuromodulation efficacy. The post-neuromodulation levels for the one or more biomarkers may be collected from the human subject within about 5 minutes to about 14 days post-neuromodulation.

An implantable medical lead having an elongated lead body extending from a proximal end to a distal end, at least one conductor extending within the lead body from the proximal end to the distal end, and a fixation member having a proximal end and a distal end, the proximal end of the electrode configured to be electrically coupled to the distal end of the lead body. The fixation member includes a first delivery port and a second delivery port for releasing a therapeutic agent from the fixation member to tissue of a patient, wherein the first delivery port is positioned along the proximal end of the fixation member to deliver the therapeutic agent to endothelial cells along an endothelial layer of tissue, and the second delivery port is positioned along the distal end of the fixation member and spaced a distance from the first delivery port to deliver the therapeutic agent to myocardial tissue within a myocardial layer of the tissue, and wherein no delivery ports are positioned within the distance that the second delivery port is spaced from the first delivery port.

Helical fixation member assembly having bi-directional controlled drug release

A stent includes a hollow wire formed into a stent pattern. The hollow wire includes an outer member, a lumen extending longitudinally within the hollow wire, at least one opening extending from an outer surface of the outer member to the lumen, and a surface area component within the hollow wire. The surface area component increases the amount of surface area available for tissue in-growth within the hollow wire. More than one surface area component may be utilized. Each surface area component may be disposed within the lumen or the at least one opening of the hollow wire. A pharmacologically or biologically active agent may be disposed within the lumen.

Drug-filled stents to prevent vessel micro-injuries and methods of manufacture thereof

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers.

Devices and associated methods for monitoring of neuromodulation using biomarkers

Growing community of inventors

Sonoma, CA, United States of America

Christopher W Storment